Key Points
- A preclinical study in a glioma model tested the combination of CarThera’s SonoCloud® blood-brain barrier opening technology with cancer immunotherapy CAR-T cells and checkpoint inhibitors.
- The results showed enhanced delivery to the tumors and surrounding brain area.
- The SonoCloud device enhanced and increased the efficacy of the checkpoint inhibitors and protected from tumor rechallenge in the untreated hemisphere.
Opening of the Blood-Brain Barrier using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma ModelsA team at MD Anderson Cancer Center led by Amy Heimberger, MD, a glioblastoma immunotherapy expert, conducted a preclinical study testing the combination of CarThera’s SonoCloud® blood-brain barrier opening technology with cancer immunotherapy CAR-T cells and checkpoint inhibitors.
The results, which show enhanced delivery to the tumors and surrounding brain area, have now been published in Clinical Cancer Research. The SonoCloud device enhanced and increased the efficacy of the checkpoint inhibitors and protected from tumor rechallenge in the untreated hemisphere.
See Clinical Cancer Research >
See CarThera’s Press Release >
*Dr. Heimberger is now affiliated with Northwestern University in Chicago.